No Clinically Significant Interaction Between Bilastine and Vortioxetine
There is no clinically significant drug interaction between bilastine (Bilaxten) and vortioxetine (Brintellix), and these medications can be safely co-administered.
Pharmacological Basis for Safety
Bilastine's Favorable Profile
Bilastine has minimal potential for drug interactions due to its unique pharmacokinetic properties 1, 2:
- No CYP450 involvement: Bilastine undergoes negligible hepatic metabolism and is almost exclusively eliminated via renal excretion unchanged
- No enzyme inhibition or induction: Does not inhibit or induce CYP450 isoenzymes
- Minimal transporter interactions: Shows only mild inhibition of MDR1, OCT1, and OATP2B1 at concentrations far exceeding therapeutic levels (≥300 μM)
- Not a substrate of major transporters: Not significantly transported by BCRP, OAT1, OAT3, or OCT2
Vortioxetine's Metabolic Pathway
Vortioxetine is primarily metabolized by CYP2D6 and other CYP450 enzymes 3, 4:
- Minimal enzyme inhibition: Has little to no effect on various CYP450 isoforms, representing a major advantage over other antidepressants
- Does not affect other medications: Not expected to markedly alter plasma concentrations of drugs metabolized by CYP enzymes
- Low pharmacodynamic interaction risk: Carries relatively low risk for pharmacodynamic interactions compared to first-generation antidepressants
Absence of Overlapping Concerns
No Shared Metabolic Pathways
Since bilastine bypasses hepatic metabolism entirely and vortioxetine's metabolism occurs through CYP450 enzymes that bilastine doesn't affect, there is no mechanism for pharmacokinetic interaction 1, 2.
No Serotonin Syndrome Risk
While vortioxetine enhances serotonergic activity, bilastine is a selective H1-antihistamine without serotonergic properties. The guidelines emphasize caution when combining serotonergic drugs 5, but bilastine does not fall into this category. Vortioxetine has no increased risk of serotonin syndrome when used at therapeutic doses without other serotonergic agents 3.
No QT Prolongation Concerns
Neither bilastine nor vortioxetine appears on lists of medications known to prolong the QT interval 6, 7. This distinguishes them from certain antihistamines (hydroxyzine, loratadine) and antidepressants that carry this risk.
Clinical Implications
No dose adjustments are required when co-administering these medications. Both drugs can be used at their standard therapeutic doses:
- Bilastine: 20 mg once daily
- Vortioxetine: 5-20 mg once daily (based on clinical response)
The combination is particularly suitable for:
- Elderly patients with both depression and allergic conditions
- Patients with hepatic or renal impairment (bilastine requires no dose adjustment in these populations) 8
- Patients on multiple medications where minimizing drug interactions is crucial
Common Pitfall to Avoid
Do not confuse bilastine with first-generation antihistamines or other second-generation antihistamines that may have different interaction profiles. Bilastine's lack of metabolism and transporter-mediated interactions makes it uniquely safe in polypharmacy situations 2.